These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4030301)

  • 1. Involutional dementias: new perspectives.
    Borromei A; Gaggi R; Giancola LC
    Ital J Neurol Sci; 1985 Jun; 6(2):167-71. PubMed ID: 4030301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piracetam plus lecithin trials in senile dementia of the Alzheimer type.
    Samorajski T; Vroulis GA; Smith RC
    Ann N Y Acad Sci; 1985; 444():478-81. PubMed ID: 3893273
    [No Abstract]   [Full Text] [Related]  

  • 3. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam.
    Herrmann WM; Stephan K
    Int Psychogeriatr; 1992; 4(1):25-44. PubMed ID: 1391670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lecithin and piracetam in Alzheimer's disease.
    Davidson M; Mohs RC; Hollander E; Zemishlany Z; Powchik P; Ryan T; Davis KL
    Biol Psychiatry; 1987 Jan; 22(1):112-4. PubMed ID: 3790634
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nonpsychotic involutional inhibited depressions and psycho-organic deteriorations: treatment with Viloxazine and piracetam].
    Borromei A; Caramelli R; Conti M; Giancola LC; Guerra L
    Minerva Med; 1989 May; 80(5):475-82. PubMed ID: 2747975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease.
    Smith RC; Vroulis G; Johnson R; Morgan R
    Psychopharmacol Bull; 1984; 20(3):542-5. PubMed ID: 6433396
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical evaluation of compounds for the treatment of memory dysfunction.
    Growdon JH; Corkin S; Huff FJ
    Ann N Y Acad Sci; 1985; 444():437-49. PubMed ID: 3893272
    [No Abstract]   [Full Text] [Related]  

  • 8. Piracetam combined with lecithin in the treatment of Alzheimer's disease.
    Growdon JH; Corkin S; Huff FJ; Rosen TJ
    Neurobiol Aging; 1986; 7(4):269-76. PubMed ID: 3528889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline.
    Parnetti L; Ciuffetti G; Mercuri M; Senin U
    Arch Gerontol Geriatr; 1985 Jul; 4(2):141-55. PubMed ID: 3899033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind investigation of piracetam (nootropil) versus placebo in the memory of geriatric inpatients.
    Abuzzahab FS; Merwin GE; Zimmermann RL; Sherman MC
    Psychopharmacol Bull; 1978 Jan; 14(1):23-5. PubMed ID: 343146
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experience with treatment by piracetam in gerontopsychiatry (author's transl)].
    Vencovský E; Hronek J; Drahokoupil L; Fait V; Hudcová T; Laciga Z; Vanková H
    Cesk Psychiatr; 1980 Apr; 76(2):89-97. PubMed ID: 6994907
    [No Abstract]   [Full Text] [Related]  

  • 12. [Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].
    Herrmann WM; Kern U
    Nervenarzt; 1987 Jun; 58(6):358-64. PubMed ID: 3302738
    [No Abstract]   [Full Text] [Related]  

  • 13. Piracetam in chronic brain failure.
    Lloyd-Evans S; Brocklehurst JC; Palmer MK
    Curr Med Res Opin; 1979; 6(5):351-7. PubMed ID: 540525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Brain performance and behavior in senile dementias of the Alzheimer type].
    Schubert H
    Wien Klin Wochenschr Suppl; 1984; 150():1-48. PubMed ID: 6592881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of Kalicor in the treatment of psycho-organic syndrome].
    Jovicić A; Miljanović B; Preradović M; Nikić S
    Vojnosanit Pregl; 1979; 36(4):284-6. PubMed ID: 506152
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug therapy of Alzheimer's disease. Problems of the criteria of clinical trials of nootropic drugs].
    Hirai S
    Nihon Rinsho; 1988 Jul; 46(7):1592-9. PubMed ID: 3221466
    [No Abstract]   [Full Text] [Related]  

  • 17. [Various therapeutic effects of piracetam (1st part)].
    Houillon P; Kitenge A; Jouannigot R; Lullien L; Cadic F
    Ann Med Psychol (Paris); 1979 Sep; 137(6-7):605-10. PubMed ID: 507608
    [No Abstract]   [Full Text] [Related]  

  • 18. Procedures in evaluating dementia--a study of conjoint application of two rating scales (SCAG and BCRS) and psychometric tests.
    Lolk A; Nielsen H; Kragh-Sørensen P
    Acta Psychiatr Scand; 1988 Nov; 78(5):592-8. PubMed ID: 3232537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of piracetam on the brain-organic psychosyndrome in cerebrovascular insufficiency. Results of a double-blind study in 40 cases].
    Trabant R; Poljakovic Z; Trabant D
    Ther Ggw; 1977 Aug; 116(8):1504-21. PubMed ID: 331549
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography.
    Heiss WD; Hebold I; Klinkhammer P; Ziffling P; Szelies B; Pawlik G; Herholz K
    J Cereb Blood Flow Metab; 1988 Aug; 8(4):613-7. PubMed ID: 3260597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.